Akebia Therapeutics IPO Research Information

Akebia Therapeutics IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Akebia Therapeutics, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Akebia Therapeutics	AKBA - NASDAQ	$14.00-$17.00	$17.00	$22.90	5.88 million	3/20/2014
Underwriter(s): Morgan Stanley, Credit Suisse
Co-Manager(s): UBS Investment Bank, Nomura
Industry: Health Care
Filing(s): Filed 2014-02-14

Akebia Therapeutics Quote & Chart - Click for current quote - AKBA

About Akebia Therapeutics (adapted from Akebia Therapeutics prospectus):
They are a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AKBA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.